The Food and Drug Administration is considering whether to approve psychedelic drugs for mental health treatment, but a prominent watchdog group is urging regulators to reject them. Citizens Commission on Human Rights International has submitted formal comments opposing the approval of psychedelics for mental disorder or emotional distress, in response to the FDA's request for input on "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs."
In its submission, CCHR argues that approval would introduce another class of psychotropic drugs with a high potential for adverse effects, including aggression, psychosis, and violence. The group's concerns center on the unique risks of classic psychedelics such as LSD, psilocybin, DMT, and mescaline, which are serotonergic agents promoted as alternatives to antidepressants. According to the National Institute on Drug Abuse, hallucinogen effects can be described as drug-induced psychosis—a distortion of a person's capacity to recognize reality, think rationally, or communicate with others.
Because psychedelics activate serotonin receptors, CCHR warns they can cause life-threatening serotonin syndrome if combined with other substances that raise serotonin, such as SSRI antidepressants. "Layering them onto people already prescribed multiple psychotropics, or already misusing substances, adds routes to psychosis, paranoia, and loss of control," said Jan Eastgate, President of CCHR International.
The group also points to the difficulty of conducting rigorous trials. The FDA's guidance notes that standard placebo controls are problematic because the drugs' effects are obvious, making blinding nearly impossible. A review of 48 trials found that blinding failed: virtually everyone in the drug group and about 93% in the placebo group correctly identified which they had received. This undermines the reliability of efficacy data.
Moreover, CCHR highlights that psychedelics are contraindicated in pregnancy, epilepsy and other seizure disorders, and severe cardiovascular disease, including uncontrolled high blood pressure, heart failure, coronary artery disease, or a prior heart attack or stroke. The group also raises concerns about informed consent, noting that a person under the influence may be unable to give or withdraw consent. Medical literature, including American Psychiatric Association publications, acknowledges this limitation.
Even if the FDA proceeds, CCHR insists on stringent conditions before any commercial dose. These include prohibiting use in anyone under 18, during pregnancy or breastfeeding, or in older adults with dementia; excluding those with a history of psychosis, mania, suicidal intent, or violence; requiring a class boxed warning and Medication Guide; mandating two trained staff in the room with no take-home supply; and implementing prescription-drug monitoring and same-day reporting of missing doses to the DEA. The group also calls for reporting sexual contact or violence to authorities within 72 hours and follow-up at 24 hours and 7, 30, and 90 days.
CCHR's position remains outright rejection. It argues that approval without these limits would simply trade one set of psychiatric-drug harms for another. "Existing psychiatric drugs already carry serious risks and have not cured any mental disability," Eastgate said. "A new class of perception-altering drugs is now offered for problems that prior psychiatric drugs have caused. That is not a scientific answer to a 'mental health crisis.' It is a replay: bold promises before long-term safety is established and no evidence the drugs can cure."
The group's detailed recommendations are outlined in CCHR's submission to the FDA. As a mental health industry watchdog, CCHR International has helped enact more than 190 worldwide reforms to protect the public from abuse. The FDA's decision could have broad implications for patients, providers, and the future of psychiatric treatment, making CCHR's warnings a critical part of the debate.
